Type 4 diabetes is a proposed term for insulin resistance that develops in older, lean people, not driven by excess weight. It is not an official medical diagnosis recognized by the American Diabetes Association or the World Health Organization. The term was introduced by researchers at the Salk Institute after a 2015 study in mice revealed that age-related insulin resistance has a fundamentally different cellular cause than the obesity-driven insulin resistance seen in type 2 diabetes.
How Type 4 Differs From Type 2
Most people associate insulin resistance with carrying extra weight. That connection is well established for type 2 diabetes, where excess body fat triggers inflammation that interferes with how cells respond to insulin. Type 4 diabetes challenges that assumption. It describes people who are not overweight or obese, yet develop insulin resistance as they age.
The distinction isn’t just clinical. The underlying biology is different. In type 2 diabetes, immune cells called macrophages drive inflammation in fat tissue, which blocks insulin signaling. In the type 4 pattern, a completely different set of immune cells is responsible: regulatory T cells, often shortened to Tregs. These are immune cells that normally help prevent the body from attacking its own tissues. In type 4 diabetes, they accumulate to abnormally high levels in fat tissue and paradoxically impair its ability to absorb glucose.
The Salk Institute team found that mice with the type 4 pattern had abnormally high levels of Tregs in their fat tissue, while mice with type 2 diabetes had abnormally low levels of those same cells, despite having more fat overall. This inverse relationship confirmed that two distinct immune processes can each lead to insulin resistance through entirely different pathways.
What Happens Inside the Body
As the body ages, Tregs gradually accumulate in visceral fat, the deep fat surrounding your organs. Research published in Nature found that these fat-resident Tregs rose to about 6.7% of immune cells in the fat tissue of aged, non-obese mice. That may sound small, but the consequences are large. The more Tregs accumulated, the less glucose the fat tissue could absorb. When researchers genetically removed these cells from mice, the fat tissue took up nearly twice the amount of glucose as normal. When they artificially expanded the Treg population, glucose uptake dropped by roughly 50%.
This creates a clear dose-response pattern: more fat-resident Tregs means worse insulin sensitivity in aging tissue. Importantly, removing these cells protected the mice from age-related insulin resistance but did nothing to prevent obesity-driven insulin resistance. The reverse was also true: therapies that block Treg accumulation reversed the type 4 pattern but had no effect on type 2. This confirmed that the two conditions, while producing similar blood sugar problems, are biologically independent.
Why It May Be Widely Underdiagnosed
Doctors typically screen for diabetes risk based on weight, family history, and lifestyle factors. A lean 70-year-old with no history of obesity might not trigger the same level of concern as someone with a higher BMI, even if their blood sugar is creeping upward. Because type 4 diabetes occurs in people who lack the traditional risk profile for type 2, researchers believe it could be frequently missed or simply lumped in with type 2.
Detecting insulin resistance in lean, elderly patients is also harder than it sounds. The most common lab measure, called HOMA-IR, varies significantly by age, sex, ethnicity, and body composition. Reference values that work well for a 40-year-old may not apply to someone in their 70s. One analysis found that insulin resistance markers behaved differently when subjects were over 60 with a HOMA-IR above 2.12, suggesting that age-specific thresholds may be necessary to catch this pattern early. Without those tailored cutoffs, cases slip through.
Where the Research Stands
Almost everything known about type 4 diabetes comes from mouse studies. The 2015 Salk Institute research demonstrated the mechanism convincingly in animals, showing that blocking Treg accumulation in fat tissue reversed age-related insulin resistance. But no large-scale human trials have confirmed the same pathway operates identically in people. Researchers are confident the concept translates, since humans also accumulate Tregs in fat tissue with age, but the term remains a research label rather than a clinical one.
On the treatment side, the mouse data points to intriguing possibilities. Therapies that selectively deplete fat-resident Tregs restored insulin sensitivity in aged mice. Separately, research into age-related inflammation has shown that certain existing medications, including metformin (already widely used for type 2 diabetes), may help by activating cellular energy pathways that counteract age-driven metabolic decline. Some researchers have also explored whether suppressing specific inflammatory signals in aging tissue could improve insulin sensitivity broadly, not just for diabetes but for other age-related conditions as well.
How It Fits Into the Diabetes Spectrum
The traditional diabetes categories are type 1 (an autoimmune attack that destroys insulin-producing cells), type 2 (insulin resistance linked to weight and lifestyle), and gestational diabetes (occurring during pregnancy). Some researchers also use “type 3 diabetes” informally to describe insulin resistance that is largely confined to the brain and associated with Alzheimer’s disease. Type 4 adds another layer, describing systemic insulin resistance driven by immune changes in aging fat tissue rather than by obesity or autoimmunity.
None of these newer labels (type 3 or type 4) appear in official diagnostic guidelines. They exist in research literature as a way to highlight that insulin resistance is not a single disease with a single cause. For older adults who maintain a healthy weight yet notice rising blood sugar levels, the type 4 concept offers a potential explanation: aging itself changes the immune landscape of fat tissue in ways that impair glucose metabolism, independent of diet, exercise, or body weight.